Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study

Leukemia

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

Am J Hematol

Molica M, Miralles G, Dillon R, Annunziata M, Basheer F, Bergua JM, Calmet FV, Campbell V, Cetin D, Cimino G, Ciotti G, Corbingi A, De Fazio L, Erol HA, Federico V, Gil C, Gulu YM, Malcorra AB, Mariani S, Mazzone C, Mulè A, Musuraca G, Khan A, Norata M, O'Nions J, Palumbo FE, Papayannidis C, Piccioni AL, Rubio MTO, Sanchez-Tovar J, Serin I, Serrao A, Sevindik OG, Sucato G, Urbano MA, Vetro C, Vives S, Rossi M, Martelli MP, Montesinos P, Othman J, Perrone S

doi: 10.1002/ajh.70142

Leukemia

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study

Br J Haematol

Kunadt D, Zukunft S, Röllig C, Metzelder S, Burchert A, Wagner-Drouet E, Kriege O, Schliemann C, Stelljes M, Ronnacker J, Bethge W, Weller JF, Steffen B, Bug G, Kouidri K, Baldus C, Fransecky L, Sala E, Platzbecker U, Metzeler K, Kayser S, Hilgendorf I, Hochhaus A, Brümmendorf TH, Jost E, Doleschall AD, Schroeder T, Kaivers J, Kordelas L, Holtick U, Unglaub JM, Sauer T, Jäger PS, Kobbe G, Stauffer E, Tischer J, Herold T, Steiner N, Nachbaur D, Kröger N, Frietsch JJ, Kraus S, Einsele H, Hänel M, Schaffrath J, Krüger W, Brandenburg A, Holderried TAW, Reinhardt L, Maulhardt M, Thiede C, Bornhäuser M, Schetelig J, Middeke JM, Stölzel F, German Cooperative Transplant Study Group and Study Alliance Leukemia (SAL)

doi: 10.1111/bjh.70735

Leukemia

Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy

Haematologica

Watts J, Madarang E, Abbott D, Hart P, Sohalski C, Zoso A, Dell-Martin J, Belachew A, Amaya ML, Kent A, McMahon C, Schwartz M, Sekeres MA, Smith C, Bradley T, Taylor J, Chandhok N, Venugopal S, Jordan C, Berg M, Haag M, Willard N, Aisner D, Schowinsky J, Pan Z, Zhang J, Gutman JA, Pollyea DA

doi: 10.3324/haematol.2025.300374

Myelodysplastic syndromes

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study

J Clin Oncol

Sallman DA, Garcia-Manero G, Daver N, Abboud CN, Stein E, Larkin K, Halpern AB, McCurdy SR, Al Malki MM, Subramanian Guru Murthy G, Silverman LR, Larson RA, Greenberg P, Gojo I, Wrobel T, Platzbecker U, Forsyth C, Vachhani P, Dong M, Shao J, Johnson LDS, Tan A, Lee C, Doshi P, Vyas P, Wei AH

doi: 10.1200/JCO-25-00617

EHA 2026

Leukemia

LB5005: PASHA trial: Gilteritinib provides similar efficacy to midostaurin in patients with newly diagnosed FLT3-mutated AML

Leukemia

Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients

Am J Hematol

Kumar S, Warraich M, Fatima M, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar AA, Saliba AN, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Foran J, Palmer J, Yi CA, Tefferi A, Gangat N

doi: 10.1002/ajh.70500

Leukemia

Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia

Am J Hematol

Jones MK, Sanchez J, Connor M, Julian K, Rezac R, Marciano K, Tobin J, Bosma G, Abbott D, Anttila K, Sohalski C, Belachew A, McMahon C, Kent A, Amaya M, Angelos MG, Schwartz M, Gutman JA, Pollyea DA

doi: 10.1002/ajh.70231

Leukemia

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study

Br J Haematol

Iriyama N, Takahashi N, Fujimaki K, Ono T, Saburi M, Yamamoto M, Kimura F, Kondo E, Aotsuka N, Yokoyama H, Katagiri S, Minami Y, Ishikawa M, Kuwatsuka Y, Miura M, Saito AM, Saito TI, Matsumura I, Miyazaki Y, Sakaida E, Maeda Y, Yamauchi T, Kiyoi H

doi: 10.1111/bjh.70678

Leukemia

Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial

Blood

Knapper S, Thomas A, Hills RK, King S, Thomas I, Marquez-Almuina N, Burns S, Gilkes AF, Irwin S, Sellar RS, Green S, Overgaard UM, Mehta P, Dennis M, Freeman SD, Russell NH

doi: 10.1182/blood.2025032681

Related content

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study

Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study

LB5005: PASHA trial: Gilteritinib provides similar efficacy to midostaurin in patients with newly diagnosed FLT3-mutated AML

Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients

Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study

Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial